Pharmacy benefit managers are at the forefront of implementing innovative contracting techniques that better align the cost of medications with their value. By offering additional tools to manage specialty drugs, including the use of specialty pharmacies, PBMs and payers are improving the quality and continuity of care patients receive, while ensuring they derive the greatest value from their medications. Over the next 10 years, PBMs and specialty pharmacies will save an estimated total of $654 billion on drug costs for health plan sponsors.
The PCMA PBM Policy Forum is designed for policy makers and staff from Capitol Hill and the Administration, as well as healthcare and drug industry advocates from think tanks, patient advocacy groups, and industry trade associations.
Conference Program Book
PBM Policy Forum 2015 Agenda
| 12:20 pm - 12:30 pm | Welcome Remarks View DetailsMark Merritt, President & Chief Executive Officer, PCMA Conference Moderator: Susan Dentzer, Senior Policy Advisor, Robert Wood Johnson Foundation | |
| 12:30 pm - 1:00 pm | Capitol Hill Perspectives on the Cost and Complexities of Drug Policy View DetailsWade Ackerman, Senior FDA Counsel, U.S. Senate Committee on Health, Education, Labor and Pensions (Minority) Paul Edattel, Professional Staff Member, U.S. House Committee on Energy and Commerce (Majority) Eric Flamm, FDA Detailee, U.S. House Committee on Energy and Commerce (Minority) Grace Stuntz, FDA Policy Advisor, Health, U.S. Senate Committee on Health, Education, Labor and Pensions Committee (Majority) | |
| 1:00 pm - 1:30 pm | How PBMs and Competition Can Maximize Future Drug Savings View DetailsWilliam Fleming, President, Humana Pharmacy Solutions, Humana Inc. Tim Wicks, Chief Executive Officer, OptumRx | |
| 1:30 pm - 2:00 pm | Government Perspectives on Biosimilars, Breakthrough Therapies and the Balancing of Affordability and Access View DetailsRichard Frank, Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services | |
| 2:00 pm - 2:30 pm | Opportunities and Barriers in the US Biosimilars Market View DetailsMark McCamish, Global Head Biopharmaceutical Development, Sandoz Inc., a Division of Novartis Christine Simmon, Senior Vice President, Policy and Strategic Alliances, GPhA | |
| 2:30 pm - 3:00 pm | PBM Industry Priorities and the Industry’s Evolution in the Specialty Market View DetailsJon Roberts, President, CVS/caremark & Executive Vice President, CVS Health | |
| 3:00 pm - 3:30 pm | PBM Industry Priorities and the Industry’s Evolution in the Specialty Market View DetailsJon Roberts, President, CVS/caremark & Executive Vice President, CVS Health | |
| 3:00 pm - 3:30 pm | Wall Street Perspective on the Pharmaceutical Supply Chain View DetailsLisa Gill, Managing Director, U.S. Equity Research, Healthcare Technology and Distribution, J.P. Morgan |
